Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.

Tuomela J, Sandholm J, Karihtala P, Ilvesaro J, Vuopala KS, Kauppila JH, Kauppila S, Chen D, Pressey C, Härkönen P, Harris KW, Graves D, Auvinen PK, Soini Y, Jukkola-Vuorinen A, Selander KS.

Breast Cancer Res Treat. 2012 Sep;135(2):481-93. doi: 10.1007/s10549-012-2181-7. Epub 2012 Jul 31.

PMID:
22847512
2.

Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells.

Sandholm J, Kauppila JH, Pressey C, Tuomela J, Jukkola-Vuorinen A, Vaarala M, Johnson MR, Harris KW, Selander KS.

Breast Cancer Res Treat. 2012 Apr;132(2):411-9. doi: 10.1007/s10549-011-1590-3. Epub 2011 May 24.

PMID:
21607583
3.

Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.

Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS.

Mol Cancer Res. 2006 Jul;4(7):437-47.

5.

Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.

Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, Selander KS.

Mol Cancer Res. 2008 Oct;6(10):1534-43. doi: 10.1158/1541-7786.MCR-07-2005.

6.

Triple-negative breast cancer: an unmet medical need.

Hudis CA, Gianni L.

Oncologist. 2011;16 Suppl 1:1-11. doi: 10.1634/theoncologist.2011-S1-01. Review.

7.

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.

Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.

Breast Cancer Res Treat. 2010 Jul;122(2):315-24. doi: 10.1007/s10549-009-0568-x. Epub 2009 Oct 1.

PMID:
19795205
8.

An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.

McCleland ML, Adler AS, Shang Y, Hunsaker T, Truong T, Peterson D, Torres E, Li L, Haley B, Stephan JP, Belvin M, Hatzivassiliou G, Blackwood EM, Corson L, Evangelista M, Zha J, Firestein R.

Cancer Res. 2012 Nov 15;72(22):5812-23. doi: 10.1158/0008-5472.CAN-12-1098. Epub 2012 Nov 8.

9.

Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines.

Qiu J, Wang X, Guo X, Zhao C, Wu X, Zhang Y.

Oncol Rep. 2009 Oct;22(4):935-41.

PMID:
19724876
10.

Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.

Schubert A, Hawighorst T, Emons G, Gründker C.

Breast Cancer Res Treat. 2011 Dec;130(3):783-90. doi: 10.1007/s10549-011-1358-9. Epub 2011 Jan 30.

PMID:
21279682
11.

Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.

Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O.

Breast Cancer Res Treat. 2010 Oct;123(3):733-45. doi: 10.1007/s10549-009-0672-y. Epub 2009 Dec 18.

PMID:
20020198
13.

Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.

Koo JS, Jung W.

Pathobiology. 2010;77(6):289-300. doi: 10.1159/000320936. Epub 2011 Jan 24.

PMID:
21266827
14.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

15.

Increased expression of osteopontin in patients with triple-negative breast cancer.

Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y, Sun J.

Eur J Clin Invest. 2008 Jun;38(6):438-46. doi: 10.1111/j.1365-2362.2008.01956.x. Epub 2008 Apr 30.

PMID:
18452545
16.

Molecular characterisation of cell line models for triple-negative breast cancers.

Grigoriadis A, Mackay A, Noel E, Wu PJ, Natrajan R, Frankum J, Reis-Filho JS, Tutt A.

BMC Genomics. 2012 Nov 14;13:619. doi: 10.1186/1471-2164-13-619.

17.

A 10-year follow-up of triple-negative breast cancer patients in Taiwan.

Lin C, Chien SY, Kuo SJ, Chen LS, Chen ST, Lai HW, Chang TW, Chen DR.

Jpn J Clin Oncol. 2012 Mar;42(3):161-7. doi: 10.1093/jjco/hyr196. Epub 2012 Jan 27.

PMID:
22287721
18.

Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.

Nguyen A, Rosner A, Milovanovic T, Hope C, Planutis K, Saha B, Chaiwun B, Lin F, Imam SA, Marsh JL, Holcombe RF.

Int J Oncol. 2005 Oct;27(4):949-56.

PMID:
16142310
19.

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.

Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O.

Hum Pathol. 2012 Jan;43(1):23-30. doi: 10.1016/j.humpath.2011.04.011. Epub 2011 Jul 20.

PMID:
21777944
20.

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.

PMID:
21562709

Supplemental Content

Support Center